Virax Biolabs Group Ltd
VRAX Nasdaq
SEC CIK 1885827
Follow Virax Biolabs
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $6.3K | −$6.1M |
| FY24 | $156.4K | −$6.7M |
| FY23 | $8.6K | −$5.5M |
| FY22 | $0 | −$1.7M |
| FY21 | $123.8K | −$651K |
| FY20 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | −838.2% | −97344.8% | −95739.2% |
| FY24 | 32.3% | −4153.3% | −4304.8% |
| FY23 | −15.9% | −66963.7% | −63748.3% |
| FY22 | - | - | - |
| FY21 | −7.6% | −520.5% | −525.8% |
| FY20 | - | - | - |
- Virax Biolabs
- Healthcare median
Show the numbers
| Year | Virax Biolabs | Healthcare median |
|---|---|---|
| FY25 | −95739.2% | −30.6% |
| FY24 | −4304.8% | −47% |
| FY23 | −63748.3% | −58% |
| FY22 | - | −80.4% |
| FY21 | −525.8% | −71.9% |
| FY20 | - | −62.2% |